



Confederation of Indian Industry
Since 1895



Department of Pharmaceuticals
Ministry of Chemicals and Fertilizers



Life Science Conclave 2010

Drug Discovery and Development

18-19 August 2010; Hotel Lalit; Barakhamba Avenue, Connaught Place, New Delhi

DRAFT PROGRAMME

Day – 1, Wednesday 18th August 2010

| | |
|-----------------------|---|
| 0800 – 1000 hrs | Registration |
| 1000 - 1130 hrs | Inaugural Session |
| 1000-1005 hrs | Welcome Address Mr. Chandrajit Banerjee Director General Confederation of Indian Industry |
| 1005-1015 hrs | Special Address Dr Anand C Burman Chairman CII National Committee on Biotechnology & Chairman, Dabur Ltd |
| 1015-1025 hrs | Special Address Dr. V. M Katoch DG, ICMR and Secretary, Health Services, Government of India |
| 1025-1035 hrs | Special Address Mr. Satish Reddy Chairman CII National Committee on Drugs and Pharmaceutical & Managing Director and Chief Operating Officer, Dr. Reddy's Laboratories Ltd |
| 1035- 1050 hrs | Keynote Address Mr. Hari Bhartia* President, Confederation of Indian Industry Co-Chairman and Managing Director, Jubilant Organosys Ltd |
| 1050-1055 hrs | Release of CII --Yes Bank Publication "Vision of Indian Life Science Sector-2015" by the Chief Guest |
| 1055-1125 hrs | Inaugural Address by the Chief Guest Mr. Gulam Nabi Azad * Honorable Minister of Health and Family Welfare |
| 1125- 1130 hrs | Concluding remarks Dr. Girdhar Gyani, Secretary General- QCI |
| 1130-1200 hrs: | Tea/Coffee |

Associate Sponsor



Knowledge Partner



Online Media Partner



1200 - 1330 Hrs

Panel Discussion: International Collaborations - Way forward

The session will deliberate on the scope and trends in furthering the collaborations between India and other countries in the field of Pharmaceuticals and Biotechnology. It is expected that concrete recommendations will come out from this forum

Session Chairman

Mr Ashok Kumar*,

Secretary, Department of Pharmaceuticals.
Ministry of Chemical & Fertilizers

Session Co-Chairman

Mr. Satish Reddy

Chairman CII National Committee on Drugs and Pharmaceutical &
Managing Director and Chief Operating Officer, Dr. Reddy's Laboratories Ltd

Dr. Kiran Majumdar Shaw *

CMD, Biocon

Dr. Hasit Joshipura

MD, GSK

Ms. Holly Vineyard

Deputy Assistant Secretary for Africa, the Middle East, and South Asia,
U.S. Department of Commerce

Dr Y K Hamied *

Chairman & Managing Director,
Cipla Ltd

Dr. Mubarak Naqvi

Director-Clinical Research
Aventis Pharma India Ltd.

1330 - 1430 hrs:

Lunch Break

1430 - 1600 Hrs

Session -I: Frontiers of Drug Design and Discovery Research

The session will deliberate on the latest trends in drug discovery research being carried out globally. The session will also focus on the concepts of discovering new potent molecules and to place them in the market. The Indian forte on drug discovery research will also be presented.

Session Chairman

Dr. Naveen Rao,

MD MSD

Development of Anti Cancer Drug- Case study

Dr Manu Jaggi,

Director, Dabur Research Foundation.

Development of Drug for Alzheimer's disease – A Case Study

Mr Venkat Jasti*

CMD,

Suven Life Sciences Ltd

Novel drug discovery research in India

Dr Kamal Sharma*

Managing Director
Lupin Ltd

Discussions

1600-1615 hrs:

Tea/Coffee

1615 - 1745 hrs

Session - II: New molecular entities and Chemical discoveries in India.

The discovery research in the emerging world especially focusing the Indian scenario will be discussed in the session. This will focus on the discovery research being undertaken by different government agencies and industry in India . The forum will deliberate to identify a rational in such discovery processes keeping Indian disease Scenario in mind.

Session Chairman

Dr.V.M Katoch

DG, ICMR and
Secretary, Health Services

Trends in Drug Designing and Development program in typical Health problems

Dr. A Surolia

Director,
National Institute of Immunology.

Trends in drug discovery and development programs in tropical diseases.

Dr Krishna Ella*

Chairman & Managing Director
Bharat Biotech International Ltd.

Trends in Vaccine development in India

Dr. V.K.Vinayak

Chief Scientific Officer
Panacea Biotec Ltd

Development of Biopharma Molecules in India

Mr. Sandeep Sahney

Managing Director
Genzyme

Discussion

1800 - 1845 Hrs

Special Session -1: Collaborative research through Industry- Academia Partnership- Intellectual property & Technology Transfer.

Session Chairman

Dr.Ananda Chakrabarty

Distinguish Professor – Microbiology
University of Illinois

Speakers

Mr. Q. Todd Dickinson, Executive Director, American Intellectual Property Law Association

Dr G J Samathanam, Advisor and Head, Technology Development & Transfer, Dept. of Science and Technology, Govt of India.

Dr Deepak Pental, Vice Chancellor, University Of Delhi*

Mr. Ranjit Shahani, Vice Chairman & Managing Director,Novartis India Ltd.*

Mr. Ashley J Stevens, President, Association of University Technology Managers(AUTM)

Highlights of CII-Yes Bank Report on Life Science Vision -2015**Session Chairman:**

Mr S Raghavan,
Joint Secretary,
Department of Biotechnology

Panelsit:

Mr Kewal Handa* Managing Director, Pfizer Ltd & Wyeth Ltd
Mr Sanjay Dalal, Torrent Pharma Ltd

1915hrs**Reception****Day 2 – Thursday, 19th August 2010****0930 – 1000 Hrs****Special Session - II****Session Chairman**

Dr. P.K.Seth
Chief Executive Officer,
Lucknow Biotech Park

Trends and Emerging Issues in Drug Drug Interactions

Dr. Charles Crespi,
Senior Vice President R & D,
BD, USA.

1000-1015 hrs:**Tea/Coffee****1015 -1145 Hrs****Sessions III: *Lab Side to Patient Side***

Different aspects of Clinical research development undertaken by International Pharma biotech Companies and their prospects will be deliberated in the session. New trends are expected to emerge through interactions..

Moderator

Dr. Surinder Singh,
Drug Control General India, Ministry of Health and Family Welfare

Clinical research development in India

Dr Ferzaan Engineer,
CEO Quintiles

Scope of Clinical trials in India,

Dr.Chandrashekhar Potkar
Director- Clinical Research
Pfizer Ltd

Approach to Clinical trials as seen by the multinational Companies

Dr Saurendra Das,
Country Manager,
Excel Life Sciences

Growth of Clinical trial Industry in India

Speaker from Jubilant

1145 - 1330 Hrs

Session –IV Regulations in Pharmaceutical and Biotechnology

The session will debate on different aspects of regulatory mechanisms prevalent in international and Indian scenario. The latest Trends on toxicity and drug safety area will also be deliberated. It is expected that deliberations in this forum will come out with relevant recommendations on the drug regulatory and toxicity aspects for the Indian drug and Pharma Industry.

Session chairman

Dr. Albinus M. D'Sa

Deputy Country Director (India) Office
U.S. Food and Drug Administration(FDA)

Concepts and norms of USFDA regulation.-

Dr Premnath Shenoy

Regulatory Affairs Director
AstraZeneca Ltd

Regulatory norms of Japanese regulatory bodies.

Speaker from Eisai

Regulatory norms of South Africa and south American-

Dr Sanjiv Sharma

Sr Vice President - Regulatory
Panacea Biotec Ltd

Road map for regulatory norms in the Indian Context

Mr Arvind Kukrety*

Assistant Drug Controller
Central Drugs Standard Control Organisation

Accreditation Process in Health Care

Dr. Girdhar Gyani , Secretary General- QCI

1330 -1430 hrs:

Lunch Break

1430 - 1530 Hrs Session –V New discovery Techniques through Instrumentation Processes

The idea behind this is to bring together the state of the art technology providers in life science research on one platform. They provide world class technologies to India, with out which no life science research can progress. Be it the molecular biology for PCR, RT-PCR, high powered DNA sequencing, Proteomics - Mass spectroscopy, chromatography, Genomics - DNA and Protein array, Cell analysis and imaging - Flow cytometry, confocal microscopy, etc. So far no efforts have been made in this country to bring the technology providers together on one platform and listen to the opportunities and challenges. The well being of this niche industry is very crucial for the success and well being of the life science research industry, be it biopharma, vaccines, biologicals, advanced clinical diagnostics, clinical research or the basic & applied research for academia, this industry plays an important role and immensely contribute to its growth.

Session Chairman

Dr. N.K Ganguly

Former DG ICMR and Secretary Health Services and Advisor Ministry of Health and Family Welfare.

Mr .Anil Nimkar,

Perkin Elmer

Mr Umesh Pawa
Vice President-India operations.
Lab India Life Sciences Pvt Ltd.

Dr Arvinder Singh
Head Science and Technology,
BD Bio Science

Mr Tanay Waingankar
Agilent Technologies.

1530 - 1645 Hrs

Session – VI Advances in Drug Delivery.

The forum will be focusing on the new concepts of drug delivery/formulation development of the drug molecules being carried out globally. This will also focus on the new concepts and trends in the formulation development areas pertaining to drug molecules.

Moderator

Dr. Rama Mukherjee
MD ARA Healthcare Pvt. Ltd

Drug Delivery a new vista in biopharma research.-

Mr Mani Iyer
Director,
Intas Biopharmaceutical Ltd.

New Drug delivery modules-
Speaker from **Zydus Cadila**

Case study in Drug Delivery research-

Speaker from Jubilant

New Horizons of Drug formulation Research

Dr Bakulesh Khammar
Executive Director- Research
Cadila Pharma

New challenge in Drug Discovery through Novel Drug Delivery

Speaker from - Dr Reddy's Laboratories Ltd

Discussions

1645 -- 1730 hrs

Session – VII: Trends In venture finance in Life Sciences.

Session Chair:

Mr. Devendra Chaudhary,
Joint Secretary,
Department of Pharmaceuticals

Dr George John, Advisor, DBT

Mr.Sanoj Ravindran, MD Asian Healthcare Fund.

Dr Sudeep Kumar, In-charge & Head- NMITLI, CSIR

Dr Mohan Kumar, Executive Director, North West Venture Partners

Discussions and recommendations